Eric Lefkofsky is Providing the Data that will Shape Tomorrows Cancer Treatments

Eric Lefkofsky is, perhaps, best known for his work in founding and building the company Groupon. This highly innovative startup has become the leading provider of group discounts to individuals. By allowing buyers to form temporary and large coalitions, Groupon has been able to provide tens of thousands of businesses with billions of dollars in sales while simultaneously saving customers billions of dollars through volume discounts and learn more about Eric.

But Lefkofksy’s activities don’t stop there. The billionaire has founded and been involved in dozens of other startups and has established himself as one of the Chicago-areas largest philanthropists. He has donated tens of millions of dollars to charitable causes, in particular, cancer research. He has also taken the Giving Pledge, a vow that many of the country’s billionaires have taken to give away at least half of their wealth over the course of their lifetimes. But even after all of this, Lefofsky was not satisfied or done making a positive mark on the world and more information click here.

In 2016, he founded tech startup Tempus. The company is dedicated to creating a vast network of data, including at the genomic level, and coupling that with world-class artificial-intelligence-based solutions that allow for unprecedented real-time insights into patterns, correlations and treatment effects and outcomes. Lefkofsky envisions Tempus being able to create the same level of information quality as full-scale studies, like the Framingham Heart Study, that previously took years to complete and tens of millions to fund. But all of this will be able to be accomplished in seconds, at the click of a mouse.

Lefkofsky also says that Tempus’ platform will allow the complete integration of both genomics data and technologies like CRISPR, which may someday be able to create on-the-spot treatments at the molecular level for various types of cancer. But in the meantime, it will be possible for oncologists and physicians to gain a level of understanding with granularity that has never before been imagines. Any one of thousands of variables and patient characteristics will be possible to analyze with respect to treatment outcomes, leading to far more effective and less side-effect-prone treatments and Eric’s lacrosse camp.

Even if these things don’t lead to a cure, they may usher in the next best thing.

More visit: